BioNotebook: Forest, Epizyme raise cash; Geron falls on imetelstat update; Revance sets IPO terms
This article was originally published in Scrip
Executive Summary
Forest Laboratories is taking on $1.8bn in debt through the sale of senior unsecured fixed-rate notes to finance its $2.9bn acquisition of Aptalis, but on a down day for biotechnology and specialty pharmaceutical stocks in general the New York-based company closed slightly higher with a 0.3% boost to $65.14 per share on 27 January.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.